Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study.
Access to care
Continuity of care
Drug detoxification center
Linkage to care
Medications for opioid use disorder
People who inject drugs
Journal
Journal of substance abuse treatment
ISSN: 1873-6483
Titre abrégé: J Subst Abuse Treat
Pays: United States
ID NLM: 8500909
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
23
11
2021
revised:
19
07
2022
accepted:
24
08
2022
pubmed:
10
9
2022
medline:
28
9
2022
entrez:
9
9
2022
Statut:
ppublish
Résumé
Access to and uptake of evidence-based treatment for substance use disorder, specifically opioid use disorder (OUD), are limited despite the high death toll from drug overdose in the United States in recent years. Patient perceived barriers to evidence-based treatment after completion of short-term inpatient medically managed withdrawal programs (detox) have not been well studied. The purpose of the current study is to elicit patients' perspectives on challenges to transition to treatment, including medications for OUD (MOUD), after detox and potential solutions. We conducted semi-structured interviews (N = 24) at a detox center (2018-2019) to explore patients' perspectives on obstacles to treatment. The study managed the data in NVivo and we used content analysis to identify themes. Patients' characteristics included the following: 54 % male; mean age 37 years; self-identified as White 67 %, Black 13 %, Latinx 8 %, Native Hawaiian/Pacific Islander 4 %, and other 8 %; heroin use in the past 3 months 67 %; and ever injecting drugs 71 %. Patients identified the following barriers: 1) lack of continuity of care; 2) limited number of detox and residential treatment program beds; 3) unstable housing; and 4) lack of options when choosing a treatment pathway. Solutions proposed by participants included: 1) increase low-barrier access to community MOUD; 2) add case managers at the detox center to establish continuity of care after discharge; 3) increase assistance with housing; and 4) encourage patient participation in treatment decisions. Patients identified lack of continuity of care, especially care coordination, as a major barrier to substance use treatment. Increasing treatment utilization, including MOUD, necessitates a multimodal approach to continuity of care, low-barrier access to MOUD, and support to address unstable housing. Patients want care that incorporates options and respect for. individualized preferences and needs.
Identifiants
pubmed: 36084559
pii: S0740-5472(22)00152-0
doi: 10.1016/j.jsat.2022.108870
pmc: PMC10084712
mid: NIHMS1880889
pii:
doi:
Substances chimiques
Heroin
70D95007SX
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108870Subventions
Organisme : NIDA NIH HHS
ID : K23 DA044085
Pays : United States
Organisme : NIDA NIH HHS
ID : P30 DA040500
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA046527
Pays : United States
Organisme : NIDA NIH HHS
ID : R25 DA013582
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no conflicts of interest to declare. Linda Sprague Martinez is an external evaluator for the Boston Public Health Commission and Action for Boston Area Development and a research consultant for BMC and The City School.
Références
Addict Sci Clin Pract. 2017 Nov 15;12(1):29
pubmed: 29141667
Psychol Bull. 1992 May;111(3):455-74
pubmed: 1594721
Diabetes Care. 2014;37(5):1246-53
pubmed: 24598245
Drug Alcohol Depend. 2021 Mar 1;220:108526
pubmed: 33465604
Drug Alcohol Depend. 2000 Feb 1;58(1-2):85-92
pubmed: 10669058
Health Promot Perspect. 2011 Dec 20;1(2):86-94
pubmed: 24688904
Health Psychol. 2006 Mar;25(2):153-62
pubmed: 16569106
JAMA. 2015 Apr 28;313(16):1636-44
pubmed: 25919527
BMJ. 2003 May 3;326(7396):959-60
pubmed: 12727768
Health Aff (Millwood). 2019 Jan;38(1):14-23
pubmed: 30615514
J Subst Abuse Treat. 2018 Aug;91:57-68
pubmed: 29910015
Am J Drug Alcohol Abuse. 2020 May 3;46(3):273-288
pubmed: 31809217
Nurse Res. 2006 Jul 1;13(4):84
pubmed: 27702218
J Subst Abuse Treat. 2016 Mar;62:68-73
pubmed: 26654934
J Addict Med. 2011 Mar;5(1):21-7
pubmed: 21359109
Soc Work. 2018 Apr 1;63(2):135-143
pubmed: 29373731
JAMA Netw Open. 2018 Jun 1;1(2):e180217
pubmed: 30646062
JAMA Netw Open. 2020 Feb 5;3(2):e1920622
pubmed: 32022884
J Addict Med. 2020 Mar/Apr;14(2):95-98
pubmed: 31567596
JAMA Netw Open. 2020 Dec 1;3(12):e2029676
pubmed: 33320266
Am J Drug Alcohol Abuse. 2019;45(1):1-10
pubmed: 30675818
AIDS Patient Care STDS. 2014 Feb;28(2):71-81
pubmed: 24428768
Nurs Health Sci. 2013 Sep;15(3):398-405
pubmed: 23480423
AIDS. 2005 May;19 Suppl 2:S67-72
pubmed: 15930843
Addiction. 2022 Sep;117(9):2450-2461
pubmed: 35315162
BMC Public Health. 2018 Aug 29;18(1):1073
pubmed: 30157815
Health Aff (Millwood). 2020 Oct;39(10):1776-1782
pubmed: 33017230
Subst Abuse Treat Prev Policy. 2020 Jan 13;15(1):4
pubmed: 31931831
J Subst Abuse Treat. 2016 Nov;70:64-72
pubmed: 27692190
Subst Use Misuse. 2019;54(14):2409-2419
pubmed: 31429351